As previously announced, Keryx Biopharmaceuticals, Inc. entered into an Agreement and Plan of Merger on June 28, 2018, as amended on October 1, 2018 (the “Merger Agreement”) with Akebia Therapeutics, Inc. (“Akebia”), and Alpha Therapeutics Merger Sub, Inc. (“Merger Sub”). In connection with the closing of the Merger and pursuant to the terms of the Merger Agreement, all of the members of Keryx's Board of Directors resigned as of the effective time of the Merger. As previously disclosed, Mark J. Enyedy, Steven C. Gilman, Michael T. Heffernan, Jodie P. Morrison and Michael Rogers will serve on the Board of Directors of Akebia.

Effective immediately following the resignations, John P. Butler was appointed as the sole director of Keryx. In addition, as of the closing of the Merger, Jodie P. Morrison's service as Interim Chief Executive Officer of Keryx ended pursuant to the terms of her employment agreement, which was previously disclosed and the other executive officers of Keryx prior to the Merger ceased to be executive officers of Keryx. Pursuant to the terms of the Merger Agreement, Nicole R. Hadas, the President and Secretary of Merger Sub, was appointed to the officer positions of President and Secretary of Keryx, which will be the only officer positions of Keryx immediately following the effective time of the Merger.

Ms. Hadas joined Akebia in 2013 and is Senior Vice President, General Counsel and Corporate Secretary.